BioCatalyst

obicetrapib 10 mg + obicetrapib/evolocumab 140 mg Q 2 weeks — catalyst calendar

1 verified catalyst event(s) referencing obicetrapib 10 mg + obicetrapib/evolocumab 140 mg Q 2 weeks, each linked to its official source. Verified as of 2026-06-22.

Upcoming

DateEventCompanyDrugOfficial source & verification
2026-11 (month)
in 4mo
ESTIMATED
 READOUT
Impact of Obicetrapib and Obicetrapib Plus Repatha on Lp(a) Levels
Phase 2 · Dyslipidemias
 NAMS NewAmsterdam Pharma Co N.V. obicetrapib 10 mg + obicetrapib/evolocum ClinicalTrials.gov ↗
✓ Source-checked 2026-06-22
Sponsor-projected date — can change
Disclaimer. Bio Catalyst Calendar is a public-events data calendar. Every date is sourced and linked to an official record (ClinicalTrials.gov, FDA / Federal Register, openFDA). It is scheduling and reference data only — NOT investment advice, a recommendation, or a buy/sell signal. Dates set by sponsors and the FDA can change; always confirm against the linked official source.